Pharma Stock Could Be Headed Towards Fresh Record Highs

MNTA is not slowing down, a historical signal says

Digital Content Manager
Sep 24, 2020 at 3:08 PM
facebook twitter linkedin


The shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) are up 0.1% to trade at $52.34 at last check, after a massive bull gap in August boosted the security to an all-time-high of $52.45 on Sept. 22. And while the equity is already enjoying an impressive 280.1% year-over-year lead, with fresh support from the 20-day moving average and a historic bull signal now flashing, more upside may be on the horizon.

Specifically, the stock's recent peak comes amid historically low implied volatility (IV), which has been a bullish combination for MNTA in the past. According to data from Schaeffer's Senior Quantitative Analyst Rocky White, there have only been two other times in the past five years when the stock was trading within 2% of a 52-week high, while its Schaeffer's Volatility Index (SVI) sat in the 20th percentile of its annual range or lower -- as is the case with the MNTA's current SVI of 18.2%, which sits slightly above the 8th percentile of its 12-month range. The data shows the security was higher a month later, averaging a return of 5.4% for that time period. From its current perch, a move of similar magnitude would put MNTA just above the $55 mark, at yet another record peak.

MNTA 2

Analysts are still skeptical of Momenta Pharmaceuticals stock, with seven of the nine in coverage carrying a tepid "hold" rating, and only the remaining two sporting a "strong buy." Meanwhile, the stock's 12-month consensus target price of $35.81 is barely a premium to its current perch. In simpler terms, there remains plenty of room for upgrades as well as price-target hikes on MNTA in the coming weeks. 

The options pits are already leaning more bullish, on the other hand. In the last 50 days, 24,455 calls have been exchanged, compared to 10,834 puts. Echoing this is MNTA's Schaeffer's put/call open interest ratio (SOIR), which stands higher than just 26% of readings from the past year. This implies short-term option traders have rarely been more call-biased.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Best stocks for October and worst stocks for October
 


 


 
Special Offers from Schaeffer's Trading Partners